Background: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) has been proposed as treatment for recurrent epithelial ovarian carcinoma. We evaluated the outcomes of CRS+ HIPEC in Recurrent Epithelial Ovarian cancers, in Indian patients. Methods: Prospective non-randomized study February 2013-Jan 2015. 26 patients with advanced Recurrent EOC, with no extra-abdominal disease treated with Secondary CRS + HIPEC in a tertiary care Cancer institution, Southern India, were analyzed. Belmonte dedicated HIPEC machine pump with Cisplatin 100mg/m2, 41.5-43 degree Celsius for 90 minutes, in platinum sensitive cases & Doxorubicin 15 mgs/m² + Cisplatin 75 mgs/m² in platinum resistant cases was used Results: 18 upfront & 8 post chemotherapy. Median peritoneal carcinomatosis Index, PCI, was 9.5 (Range 3-19). Average surgery duration 9 hrs (Range 5.5 – 19). No 60 days mortality. Duration of hospital stay (p < 0.001), gastrointestinal recovery (p = 0.039), infection type (p = 0.036), ARDS (p = 0.041) correlates with extent of cytoreduction. 24 patients achieved CC0, and 2 pts CC1. Bowel resection required in 34.6 %. Diaphragm stripping was required in 30.7% with resection in 7.6%. Median hospital stay was 12 days (range: 10-42 days) Bowel fistula happened in 7.6% cases requiring re-exploration, temporary stomas, wound related complications in 26%. At median follow-up of twelve months, 11.5% recurrences ( Both Paltinum resistant cases recurred in peritoneal cavity and one pt also in Liver Parenchyma) and One platinum sensitive pt recurred isolated in Peritoneal cavity. One death (Pulmonary embolism at 5th month of f/u was observes). Remaining 23 patients are disease free till to date. Conclusions: In our Indian study, secondary cytoreduction and HIPEC is shown to be very promising in Recurrent Epithelial Ovarian cancers pts with no extra-abdominal disease & good Performance status and can be done with acceptable morbidity, using dedicated HIPEC machine resulting in good peritoneal control of disease & DFS. The benefit of HIPEC in our study was limited to platinum sensitive recurrent cases only and not to platinum resistant cases.